Earnings Tuesday Preview: Palo Alto, BP, Eli Lilly Lead

Major publicly traded companies, including Palo Alto Networks, BP p.l.c., and Eli Lilly and Company, are scheduled to release their quarterly financial results before the market open on Tuesday, 4 August 2026. These reports will provide critical data points on the health of the cybersecurity, energy, and pharmaceutical sectors, offering signals for broader market sentiment. The S&P 500 closed the prior session at 5,850, up 14% year-to-date, setting a high bar for corporate performance.

Context — [why this matters now]

Earnings season enters its second week with investor focus shifting from mega-cap technology to a broader cross-section of the global economy. The macroeconomic backdrop is defined by the Federal Reserve's current pause at a 4.75% terminal rate, which has pressured growth stock valuations while benefiting value and income-oriented sectors. These reports serve as a real-time stress test for corporate profitability amid persistent inflation and moderating consumer demand.

Cybersecurity remains a non-discretionary budget item for enterprises, insulating the sector from broader IT spending cuts. The last major earnings surprise from Palo Alto Networks occurred in February 2026, when billings guidance exceeded analyst estimates by 8%, sending shares up 18% in a single session. For integrated energy firms like BP, the primary focus is on capital allocation, specifically the sustainability of shareholder returns if commodity prices retreat from current levels.

Data — [what the numbers show]

Palo Alto Networks is projected to report fiscal Q4 2026 revenue of $6.15 billion, representing 18% year-over-year growth. The consensus adjusted EPS estimate is $2.22. Billings growth, a key forward-looking metric for SaaS companies, is forecast at 16%.

BP is expected to post Q2 2026 revenue of $53.8 billion. The consensus adjusted net income is $4.1 billion. The prior quarter’s dividend of $0.4366 per share will be scrutinized for any increase or change in the company’s buyback program, previously set at $1.75 billion per quarter.

Eli Lilly’s Q2 2026 revenue consensus is $10.4 billion, with adjusted EPS of $3.28. Sales of its GLP-1 drugs, Mounjaro and Zepbound, are estimated to have reached $6.8 billion for the quarter, a 60% increase from the same period last year. This compares to rival Novo Nordisk’s Ozempic sales of $5.2 billion in its most recent quarter.

Analysis — [what it means for markets / sectors / tickers]

Strong results from Palo Alto Networks would likely buoy the entire cybersecurity ETF (HACK), which holds positions in CrowdStrike and Zscaler. A 10% earnings beat could add an estimated $12 billion to the sector’s aggregate market capitalization. Conversely, a miss on billings guidance would signal enterprise contract delays, negatively impacting software peers like Fortinet.

For BP, capital discipline is paramount. A maintained or raised dividend reinforces the energy sector (XLE) as a source of reliable yield, particularly if commentary suggests stable production targets. However, any reduction in shareholder returns would trigger outflows from the American Depository Receipts of European oil majors, including Shell and TotalEnergies.

Eli Lilly’s sales figures will directly impact the biotech sector (XBI). A significant beat could lift peers like Viking Therapeutics and Amgen, which are developing competing weight-loss therapies. The primary counter-argument is that GLP-1 drug revenue growth, while spectacular, is already fully priced into Lilly’s premium valuation. Hedge fund positioning data shows net long exposure to pharmaceutical stocks at a 12-month high.

Outlook — [what to watch next]

Immediate market reactions will set the tone for Wednesday’s session, which features earnings from Qualcomm and Kraft Heinz. The July Jobs Report, due Friday 7 August, is the next major macroeconomic catalyst with power to override individual stock stories.

For Palo Alto, watch the stock’s reaction to its product segment growth; support sits at the 50-day moving average of $315. For BP, the Brent crude oil futures price above $84 per barrel is the key variable for cash flow projections. Eli Lilly investors will monitor for any updated full-year revenue guidance, currently set at $42.5 billion.

Frequently Asked Questions

What time does Palo Alto Networks report earnings?

Palo Alto Networks is scheduled to release its fiscal fourth-quarter 2026 results at 4:05 PM Eastern Time on Monday, 3 August, with a conference call to follow at 5:00 PM ET. The earnings release before the Tuesday market open allows investors to react to the numbers at the bell. This timing is standard practice for the company and many other technology firms.

How does BP's dividend yield compare to other oil companies?

BP's forward dividend yield is approximately 4.8%, based on its most recent payout. This is broadly in line with Shell's yield of 4.6% but slightly below TotalEnergies' 5.1%. ExxonMobil and Chevron offer yields of 3.5% and 4.0%, respectively. The variance reflects differing corporate strategies on balancing shareholder returns with energy transition investments.

Why are Eli Lilly's GLP-1 drugs so important to its stock price?

Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, for diabetes and obesity are its primary growth engines, accounting for over 65% of total revenue. Analyst projections show this segment driving nearly all of the company's earnings growth for the next three years. The stock’s performance is highly correlated with quarterly sales figures and prescription data for these specific medications.

Bottom Line

Tuesday’s earnings will test sector-specific demand against a backdrop of elevated market expectations.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.